Kalytera Therapeutics Inc. Stock Price - KALTF

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Kalytera Therapeutics Inc. (QB) KALTF OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.0002 -0.51% 0.039 0.04 0.03 0.0367 0.0392 16:01:54
Bid Price Ask Price Spread Spread % News
0.01 0.044 0.034 77.27% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
49 96,549 $ 0.037014 $ 3,574 177,021 0.01565 - 0.0878
Last Trade Time Type Quantity Stock Price Currency
15:20:48 150 $ 0.039 USD

Kalytera Therapeutics Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 20.14M 516.46M $ 6.94M - - 498.65M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
157.57k $ - 0.00% - -

more financials information »

Kalytera Therapeutics Inc. News

Loading Messages....

Latest KALTF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical KALTF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.0240.040.0240.0361818108,7580.01562.5%
1 Month0.0210.040.016850.0297531174,2020.01885.71%
3 Months0.030.040.015650.0280969175,8630.00930.0%
6 Months0.03990.0440.015650.0337155242,313-0.0009-2.26%
1 Year0.0610.08780.015650.0415127241,593-0.022-36.07%
3 Years0.3590.610.015650.1051917189,077-0.32-89.14%
5 Years0.00190.610.00010.105118183,5800.03711,952.63%

Kalytera Therapeutics Inc. Description

Kalytera Therapeutics is a clinical-stage pharmaceutical company pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on Graft versus Host Disease ("GvHD"). Kalytera is also developing a new class of proprietary cannabidiol ("CBD") therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera has filed composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.

Your Recent History
Kalytera T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.